MetaCap

Abivax SA (ABVX) vs Cytokinetics (CYTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cytokinetics (CYTK) has outperformed Abivax SA (ABVX) over the past year, losing 22.4% versus a loss of 38.5%. Cytokinetics is the larger company by market cap ($7.07 billion vs $6.41 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVX-38.55%CYTK-22.40%
+37%-3%-43%
Nov 21, 20251 yearNov 20, 2026
ABVX+781.93%CYTK+53.37%
+1727%+803%-120%
Oct 16, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVX versus CYTK key metrics
MetricABVXCYTK
Share price$73.20$50.78
Market cap$6.41B$7.07B
1-day change-9.24%-1.32%
YTD return-45.72%-20.08%
1-year return-38.55%-22.40%
5-year return—+30.11%
EPS (TTM)$-6.08$-6.02
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$88.04M
Revenue growth (YoY)—+376.56%
Net income (latest FY)—$-784.96M
Operating margin—-695.44%
Net margin—-891.60%
52-week high$148.83$88.31
52-week low$62.70$50.32
Distance from 52-week high-50.82%-42.50%
Analyst consensusnonestrong_buy
Avg. price target upside+123.47%+115.48%
Average volume1.35M2.02M
Shares outstanding87.54M139.30M
Employees98673
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CYTK has outperformed ABVX by 16.1 percentage points over the past year.

About Abivax SA

ABVX stock →

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 98 employees

About Cytokinetics

CYTK stock →

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees

ABVX vs CYTK FAQ

Which is bigger, Abivax SA or Cytokinetics?

Cytokinetics (CYTK) is larger, with a market capitalization of $7.07B compared with $6.41B for Abivax SA (ABVX).

Which stock has performed better over the past year, ABVX or CYTK?

CYTK returned -22.40% over the past 12 months, compared with -38.55% for ABVX (price return, excluding dividends). Past performance does not predict future results.

Are Abivax SA and Cytokinetics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons